Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone011-44-0-203-3846700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees100
Next Earnings DateN/A
OptionableNot Optionable
Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions
What is Orchard Therapeutics' stock symbol?
Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."
What price target have analysts set for ORTX?
4 brokerages have issued 12 month price targets for Orchard Therapeutics' stock. Their predictions range from $16.80 to $27.00. On average, they anticipate Orchard Therapeutics' stock price to reach $22.45 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.
What is the consensus analysts' recommendation for Orchard Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.
Has Orchard Therapeutics been receiving favorable news coverage?
Media stories about ORTX stock have been trending somewhat negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Orchard Therapeutics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Orchard Therapeutics' key competitors?
Some companies that are related to Orchard Therapeutics include argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC) and Momenta Pharmaceuticals (MNTA).
What other stocks do shareholders of Orchard Therapeutics own?
Who are Orchard Therapeutics' key executives?
Orchard Therapeutics' management team includes the folowing people:
- Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
- Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
- Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
- Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 55)
- Mr. John Ilett, Gen. Counsel & Company Sec.
When did Orchard Therapeutics IPO?
(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does Orchard Therapeutics' lock-up period expire?
Orchard Therapeutics' lock-up period expires on Monday, April 29th. Orchard Therapeutics had issued 14,285,715 shares in its initial public offering on October 31st. The total size of the offering was $200,000,010 based on an initial share price of $14.00. After the expiration of Orchard Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Who are Orchard Therapeutics' major shareholders?
Orchard Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include RA Capital Management LLC (5.77%), Temasek Holdings Private Ltd (1.19%), Baillie Gifford & Co. (1.10%), Foresite Capital Management IV LLC (0.80%), Perceptive Advisors LLC (0.62%) and Massachusetts Financial Services Co. MA (0.53%).
Which major investors are buying Orchard Therapeutics stock?
ORTX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Temasek Holdings Private Ltd, Baillie Gifford & Co., Foresite Capital Management IV LLC, Perceptive Advisors LLC, Massachusetts Financial Services Co. MA, Sphera Funds Management LTD. and Millennium Management LLC.
How do I buy shares of Orchard Therapeutics?
Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orchard Therapeutics' stock price today?
One share of ORTX stock can currently be purchased for approximately $15.7785.
How big of a company is Orchard Therapeutics?
Orchard Therapeutics has a market capitalization of $1.33 billion. Orchard Therapeutics employs 100 workers across the globe.
What is Orchard Therapeutics' official website?
How can I contact Orchard Therapeutics?
Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.
MarketBeat Community Rating for Orchard Therapeutics (NASDAQ ORTX)
MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote "Outperform" if you believe ORTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
